Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) closed the day trading at $557.91 down -2.30% from the previous closing price of $571.06. In other words, the price has decreased by -$2.30 from its previous closing price. On the day, 0.84 million shares were traded. REGN stock price reached its highest trading level at $575.2 during the session, while it also had its lowest trading level at $553.0.
Ratios:
For a better understanding of REGN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.64. For the most recent quarter (mrq), Quick Ratio is recorded 3.95 and its Current Ratio is at 4.73. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 05, 2025, Upgraded its rating to Outperform and sets its target price to $834 from $762 previously.
On January 16, 2025, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $1130 to $738.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 01 ’24 when McCourt Marion sold 1,000 shares for $844.61 per share. The transaction valued at 844,610 led to the insider holds 12,931 shares of the business.
MARION E MCCOURT bought 1,000 shares of REGN for $844,610 on Nov 01 ’24. On Oct 01 ’24, another insider, RYAN ARTHUR F, who serves as the Director of the company, sold 100 shares for $1048.78 each. As a result, the insider received 104,878 and left with 17,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 60993507328 and an Enterprise Value of 53636440064. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.57, and their Forward P/E ratio for the next fiscal year is 12.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.82. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.29 while its Price-to-Book (P/B) ratio in mrq is 2.08. Its current Enterprise Value per Revenue stands at 3.777 whereas that against EBITDA is 11.59.
Stock Price History:
The Beta on a monthly basis for REGN is 0.45, which has changed by -0.38091856 over the last 52 weeks, in comparison to a change of 0.07455289 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $1211.20, while it has fallen to a 52-week low of $525.99. The 50-Day Moving Average of the stock is -15.51%, while the 200-Day Moving Average is calculated to be -35.73%.
Shares Statistics:
Over the past 3-months, REGN traded about 1.01M shares per day on average, while over the past 10 days, REGN traded about 1252990 shares per day. A total of 107.80M shares are outstanding, with a floating share count of 105.40M. Insiders hold about 3.59% of the company’s shares, while institutions hold 86.42% stake in the company. Shares short for REGN as of 1743379200 were 2790935 with a Short Ratio of 2.76, compared to 1740700800 on 2565723. Therefore, it implies a Short% of Shares Outstanding of 2790935 and a Short% of Float of 2.69.
Dividends & Splits
REGN’s forward annual dividend rate is 0.88, up from 0.0 a year ago. Against a Trailing Annual Dividend Yield of 0.0
